Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials

Kristine M. Erlandson, Christoph C Carter, Kathleen Melbourne, +15

Clinical Infectious Diseases

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen

Zoë Fox, Andrew Phillips, Cal Cohen, +7

AIDS

Effect of Prolonged Discontinuation of Successful Antiretroviral Therapy on CD4⁺T Cell Decline in Human Immunodeficiency Virus–Infected Patients: Implications for Intermittent Therapeutic Strategies

Pablo Tebas, Keith Henry, Kristin Mondy, +4

The Journal of Infectious Diseases

Intermittent Therapeutic StrategiesImmunologyCd4 T Cell ResponsesImmunotherapyHuman Retrovirus +14

Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts

Dathan M. Byonanebye, Mark N. Polizzotto, Fernando Maltêz, +22

The Lancet HIV

Respond Consortium CohortsHypertensionPreventive MedicineCardiovascular EpidemiologyCardiovascular Disease +12

STAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non‐inferior to efavirenz/emtricitabine/tenofovir DF in ART‐naïve adults

Cal Cohen, DA Wohl, José Ramón Arribas, +10

Journal of the International AIDS Society

Superior EfficacyFda Snapshot AlgorithmSingle Tablet RegimenTreatment And PreventionPharmacology +11

Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study

Danielle Porter, Martin Daeumer, Alexander Thielen, +5

Viruses

An update on HIV-testing at a London sexually transmitted diseases clinic: long-term impact of the AIDS media campaigns.

Eduard J. Beck, C Donegan, Colin Kenny, +7

Sexually Transmitted Infections

Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment‐naïve, HIV‐1‐infected patients

Cal Cohen, Pedro Cahn, Bonaventura Clotet, +10

Journal of the International AIDS Society

Treatment And PreventionHuman RetrovirusWeek 48Tmc278 Vs EfvHiv Infection +11

The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2

Joy Y. Feng, Venice Du Pont, Darius Babusis, +12

Molecules

Inflammatory Lung DiseaseLung InflammationNucleoside/nucleotide Analogs TenofovirImmunologyImmunotherapeutics +14

Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression

José Castillo‐Mancilla, Mary Morrow, Peter W. Hunt, +14

Open Forum Infectious Diseases